OncRef

Clinical Trial: NCT04978584

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:M.D. Anderson Cancer Center
Information Provided By:M.D. Anderson Cancer Center
Last Update Posted:2026-10-06

Study Overview

Brief Summary

This phase II trial studies the effect of rituximab, lenalidomide, acalabrutinib, tafasitamab alone and in combination with chemotherapy in treating patients with newly diagnosed non-germinal center diffuse large B-cell lymphoma. Rituximab and tafasitamab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. Acalabrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, cyclophosphamide, doxorubicin, and vincristine, and work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving rituximab, lenalidomide, acalabrutinib, tafasitamab alone and with combination chemotherapy may help control non-germinal center diffuse large B-cell lymphoma.

Official Title

Smart Stop: A Phase II Trial of Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Prior to and With Standard Chemotherapy for Patients With Newly Diagnosed DLBCL

Conditions

Diffuse Large B-Cell Lymphoma

Intervention / Treatment

  • Drug: Acalabrutinib
  • Drug: Cyclophosphamide
  • Drug: Doxorubicin Hydrochloride
  • Drug: Lenalidomide
  • Drug: Prednisone
  • Biological: Rituximab
  • Biological: Tafasitamab
  • Drug: Vincristine

Other Study ID Numbers

  • 2021-0046
  • NCI-2021-04298
  • 2021-0046

Start Date (Actual)

2022-03-03

Primary Completion Date (Estimated)

2027-01-16

Study Completion Date (Estimated)

2027-01-16

Enrollment (Actual)

62

Study Type

Interventional

Phase

Phase 2